{"id":"NCT02729025","sponsor":"Amgen","briefTitle":"Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))","officialTitle":"A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-14","primaryCompletion":"2018-04-05","completion":"2018-04-05","firstPosted":"2016-04-06","resultsPosted":"2019-04-23","lastUpdate":"2022-09-23"},"enrollment":129,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Subjects With Hyperlipidemia, Dyslipidemia"],"interventions":[{"type":"DRUG","name":"Evolocumab","otherNames":["Repatha","AMG 145"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Evolocumab 420 mg QM","type":"EXPERIMENTAL"}],"summary":"A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).","primaryOutcome":{"measure":"Percent Change From Baseline in Maximum Target-to-background Ratio in the Most Diseased Segment of the Index Vessel at Week 16","timeFrame":"Baseline and week 16","effectByArm":[{"arm":"Placebo","deltaMin":-5.31,"sd":1.67},{"arm":"Evolocumab 420 mg QM","deltaMin":-8.31,"sd":1.67}],"pValues":[{"comp":"OG000 vs OG001","p":"0.18"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":15,"countries":["United States","Canada","Netherlands"]},"refs":{"pmids":["30561610","33078867","32393252","32268367"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":64},"commonTop":["Nasopharyngitis","Headache","Influenza","Influenza like illness","Diarrhoea"]}}